Literature DB >> 29226535

Commentary on Fraser et al. (2018): Evidence base for harm reduction services-the urban-rural divide.

Kathryn E Lancaster1, Carlos D Malvestutto2, William C Miller1, Vivian F Go3.   

Abstract

Entities:  

Keywords:  harm reduction; hepatitis C virus; medication-assisted treatment; opioid use; people who inject drugs; syringe service programs

Mesh：

Year:  2018        PMID： 29226535      PMCID： PMC6715287          DOI： 10.1111/add.14052

Source DB:  PubMed          Journal:  Addiction        ISSN： 0965-2140            Impact factor:   6.526


× No keyword cloud information.
  9 in total

1.  Self-reported hepatitis C virus antibody status and risk behavior in young injectors.

Authors:  Holly Hagan; Jennifer Campbell; Hanne Thiede; Steffanie Strathdee; Lawrence Ouellet; Farzana Kapadia; Sharon Hudson; Richard S Garfein
Journal:  Public Health Rep       Date:  2006 Nov-Dec       Impact factor: 2.792

2.  Syringe Service Programs for Persons Who Inject Drugs in Urban, Suburban, and Rural Areas - United States, 2013.

Authors:  Don C Des Jarlais; Ann Nugent; Alisa Solberg; Jonathan Feelemyer; Jonathan Mermin; Deborah Holtzman
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-12-11       Impact factor: 17.586

3.  Factors influencing smokeless tobacco use in rural Ohio Appalachia.

Authors:  Julianna M Nemeth; Sherry T Liu; Elizabeth G Klein; Amy K Ferketich; Mei-Po Kwan; Mary Ellen Wewers
Journal:  J Community Health       Date:  2012-12

4.  Individual and network factors associated with non-fatal overdose among rural Appalachian drug users.

Authors:  Jennifer R Havens; Carrie B Oser; Hannah K Knudsen; Michelle Lofwall; William W Stoops; Sharon L Walsh; Carl G Leukefeld; Alex H Kral
Journal:  Drug Alcohol Depend       Date:  2010-12-03       Impact factor: 4.492

Review 5.  Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.

Authors:  Jaimie P Meyer; Yavar Moghimi; Ruthanne Marcus; Joseph K Lim; Alain H Litwin; Frederick L Altice
Journal:  Int J Drug Policy       Date:  2015-05-17

6.  Provider Workforce Assessment in a Rural Hepatitis C Epidemic: Implications for Scale-up of Antiviral Therapy.

Authors:  Ryan P Westergaard; Lauren J Stockman; Heather A Hyland; Sheila M Guilfoyle; John J Fangman; James M Vergeront
Journal:  J Prim Care Community Health       Date:  2014-11-24

7.  Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic.

Authors:  Hannah Fraser; Jon Zibbell; Thomas Hoerger; Susan Hariri; Claudia Vellozzi; Natasha K Martin; Alex H Kral; Matthew Hickman; John W Ward; Peter Vickerman
Journal:  Addiction       Date:  2017-09-20       Impact factor: 6.526

Review 8.  Complexities of HCV management in the new era of direct-acting antiviral agents.

Authors:  W M Rosenberg; S Tanwar; P Trembling
Journal:  QJM       Date:  2013-09-23

Review 9.  Acute hepatitis C: management in the rapidly evolving world of HCV.

Authors:  Suraj A Sharma; Jordan J Feld
Journal:  Curr Gastroenterol Rep       Date:  2014-02
  9 in total
  3 in total

1.  Syringe Service Program Utilization, Barriers, and Preferences for Design in Rural Appalachia: Differences between Men and Women Who Inject Drugs.

Authors:  Kathryn E Lancaster; Hannah L F Cooper; Christopher R Browning; Carlos D Malvestutto; John F P Bridges; April M Young
Journal:  Subst Use Misuse       Date:  2020-08-04       Impact factor: 2.164

2.  Physician blame and vulnerability: novel predictors of physician willingness to work with patients who misuse opioids.

Authors:  Berkeley Franz; Lindsay Y Dhanani; Daniel L Brook
Journal:  Addict Sci Clin Pract       Date:  2021-05-25

3.  The Relationship Between Hepatitis C Virus Rates and Office-Based Buprenorphine Access in Ohio.

Authors:  Daniel L Brook; Angela T Hetrick; Shibani R Chettri; Christine A Schalkoff; Adams L Sibley; Kathryn E Lancaster; Vivian F Go; William C Miller; David M Kline
Journal:  Open Forum Infect Dis       Date:  2021-05-17       Impact factor: 3.835
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.